NetworkNewsBreaks – Champignon Brands Inc. (CSE:
Post# of 25
(Total Views: 179)
Posted On: 01/25/2021 4:41:03 PM
NetworkNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Opens New CRTCE Clinic to Provide Ketamine Treatment for Adults with Depression
Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions, has opened its third Canadian Rapid Treatment Center of Excellence (“CRTCE”) clinic. Champignon chairman and CEO Roger McIntyre announced the opening of the center; the announcement noted that the clinics — the other two are located in Mississauga and Toronto — are focused on the treatment of depression and suicide through novel ketamine therapy treatment. The company noted in the announcement that more than 20 clinical trials have been conducted that demonstrate the effectiveness of ketamine and esketamine in treating patients who have failed to respond to conventional antidepressants. Champignon’s CRTCE clinics are the first of their kind in Canada. They specialize in providing breakthrough rapid onset treatments for depression including but not limited to intravenous ketamine and intranasal esketamine. “The opening of our first Ottawa CRTCE Clinic provides an opportunity for CRTCE to provide access to new treatments for people who are suffering from depression,” said Champignon chairman and CEO Roger McIntyre in the press release. “In addition to providing clinical care, all CRTCE Clinics conduct research that aims to improve the quality of people’s lives affected by these common and debilitating disorders in Canada.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions, has opened its third Canadian Rapid Treatment Center of Excellence (“CRTCE”) clinic. Champignon chairman and CEO Roger McIntyre announced the opening of the center; the announcement noted that the clinics — the other two are located in Mississauga and Toronto — are focused on the treatment of depression and suicide through novel ketamine therapy treatment. The company noted in the announcement that more than 20 clinical trials have been conducted that demonstrate the effectiveness of ketamine and esketamine in treating patients who have failed to respond to conventional antidepressants. Champignon’s CRTCE clinics are the first of their kind in Canada. They specialize in providing breakthrough rapid onset treatments for depression including but not limited to intravenous ketamine and intranasal esketamine. “The opening of our first Ottawa CRTCE Clinic provides an opportunity for CRTCE to provide access to new treatments for people who are suffering from depression,” said Champignon chairman and CEO Roger McIntyre in the press release. “In addition to providing clinical care, all CRTCE Clinics conduct research that aims to improve the quality of people’s lives affected by these common and debilitating disorders in Canada.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)